Agency Business briefs

Share this article:
InVentiv Health acquired French healthcare marketing and communications network Substrat'Homme SA. The Paris-based network has partnered with inVentiv since 2009. Its seven healthcare-focused shops will be part of the inVentiv Communications Global Alliance.

APCO Worldwide named former Pfizer public affairs director Francesca Tedesco VP. Tedesco headed Pfizer's specialty care public affairs, covering vaccines, infectious disease, oncology, ophthalmology and endocrine products.

Waggener Edstrom, a Seattle PR shop, named SVP Colleen Beauregard to lead the healthcare practice. Beauregard replaces Jenny Moede in that role. Moede was promoted to EVP North America.

Dendreon signed on with a new agency, San Francisco-based Division of Labor, launched by a pair of former McCann executive creative directors. Other founding clients at the shop include Microsoft and the LA Marathon.

Publicis rebranded its Strategic Solutions Group as Publicis Touchpoint Solutions, including four previously independent businesses – Publicis Selling Solutions, Arista, Pharmagistics and Scientific Voice.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?